美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NETLease Corporate Real Estate ETF

24.88

-0.4600-1.82%

成交量：7.03萬

成交額：177.85萬

市值：4,789.40萬

市盈率：- -

高：25.45

開：25.41

低：24.80

收：25.34

52周最高：28.43

52周最低：23.56

股本：192.50萬

流通股本：192.50萬

量比：1.19

換手率：3.65%

股息：1.26

股息率：5.04%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

AvalonBay Communities（AVB）與Equity Residential（EQR）合併房地產投資信託基金預估市值可達530億美元

科倫藥業(002422.SZ)：TROP2 ADC蘆康沙妥珠單抗(sac-TMT)新增適應症上市申請獲受理

受租金收入增長提振，VICI上調了2026年基金運營收入（FFO）預測

VICI Properties 更新2026財年調整後運營資金指引：上調至26.75億-27億美元，每股2.45-2.47美元

Sonesitatug vedotin 在 CLDN18.2陽性晚期胃癌/胃食管結合部癌的二線及後線治療中，顯示出具有統計學顯著性且重要臨床意義的總生存期（OS）改善

科倫藥業(002422.SZ)：科倫博泰新型雙載荷ADC藥物SKB565新藥臨床試驗(IND)申請獲批

英派藥業首個雙載荷ADC成果落地：IMP3201被提名為臨床前候選化合物

百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)臨床試驗完成首例受試者入組

Biohaven將在ESMO大會公布BHV-1530 ADC新藥臨床數據

环球市场播报

科倫博泰TROP2 ADC實現「全球首個」：PD-L1陰性一線NSCLC III期達PFS主要終點

每日经济新闻

消息人士稱，AirTrunk計劃於9月或10月在新加坡推出房地產投資信託基金首次公開發行，有望籌資約15億美元。

美國研究綜述-Equinix、高盛、摩根大通

科倫藥業：TROP2 ADC聯合療法肺癌3期臨床達主要終點

超2萬億元！上海三大先導產業交出倍增答卷

據天空新聞報道，英國超市莫里森斯正就一筆價值8.03億美元的門店交易進行談判

港股異動 | 百奧賽圖-B(02315)升逾14% 近日與Whitehawk達成全球合作共同開發創新雙特異性抗體ADC

豪華酒店房地產投資信託基金Braemar Hotels & Resorts回應Al Shams不實指控

环球市场播报

安捷倫(A)擴充Altura色譜柱產品線兩款新品適配多肽、ADC、mRNA等生物藥檢測

從「旁觀者」到「追趕者」：諾華(NVS.US)斥資15億美元收購Myricx，ADC賽道再落關鍵一子

Realty Income攜手Cloud Capital及全球機構投資者組建程序化合資企業，投資超大規模數據中心，初始種子資產估值超60億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/NETL/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NETL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","market":"US","secType":"STK","nameCN":"NETLease Corporate Real Estate ETF","latestPrice":24.88,"timestamp":1789588800000,"preClose":25.34,"halted":0,"volume":70331,"delay":0,"changeRate":-0.018153117600631447,"floatShares":1925000,"shares":1925000,"eps":0,"marketStatus":"盤前交易","change":-0.46,"latestTime":"09-17 06:37:30 EDT","open":25.41,"high":25.445,"low":24.8,"amount":1778507.259432,"amplitude":0.025454,"askPrice":28.35,"askSize":100,"bidPrice":21.81,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":24.88,"sharesOutstanding":1775000,"nav":25.33,"aum":48760250,"dividendRate":0.050442,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.88,"preClose":24.88,"latestTime":"19:30 EDT","volume":8,"amount":199.04,"timestamp":1789601404017,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.186128246966079,"impliedVol":0.0687,"impliedVolPercentile":0.092},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","floatShares":1925000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.186128246966079,"shares":1925000,"dividePrice":1.255,"high":25.445,"amplitude":0.025454,"preClose":25.34,"low":24.8,"week52Low":23.56,"pbRate":"--","week52High":28.4299,"institutionHeld":0,"latestPrice":24.88,"eps":0,"divideRate":0.050442,"volume":70331,"delay":0,"ttmEps":0,"open":25.41,"prevYearClose":23.727,"prevWeekClose":25.5596,"prevMonthClose":26.1278,"prevQuarterClose":26.7001,"fiveDayClose":25.89,"twentyDayClose":26.3268,"sixtyDayClose":26.0377},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NETL\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-08-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-27","defaultRemindTime":1787837400000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-27","currency":"USD","dateTimestamp":1787803200000,"payDate":"2026-08-31"},{"date":"2026-07-29","symbol":"NETL","amount":0.105,"announcedDate":"2026-07-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-29","defaultRemindTime":1785331800000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-31","payableDate":"2026-07-29","currency":"USD","dateTimestamp":1785297600000,"payDate":"2026-07-31"},{"date":"2026-06-26","symbol":"NETL","amount":0.105,"announcedDate":"2026-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-26","defaultRemindTime":1782480600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-26","currency":"USD","dateTimestamp":1782446400000,"payDate":"2026-06-30"},{"date":"2026-05-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-05-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-27","defaultRemindTime":1779888600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-27","currency":"USD","dateTimestamp":1779854400000,"payDate":"2026-05-29"},{"date":"2026-04-28","symbol":"NETL","amount":0.105,"announcedDate":"2026-04-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-28","defaultRemindTime":1777383000000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-30","payableDate":"2026-04-28","currency":"USD","dateTimestamp":1777348800000,"payDate":"2026-04-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NETL\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-30","recordDate":"2019-12-31","paymentDate":"2020-01-02","value":0.031935,"currency":"USD"},{"executeDate":"2020-03-17","recordDate":"2020-03-18","paymentDate":"2020-03-19","value":0.0097783,"currency":"USD"},{"executeDate":"2020-03-31","recordDate":"2020-04-01","paymentDate":"2020-04-02","value":0.1912399,"currency":"USD"},{"executeDate":"2020-06-26","recordDate":"2020-06-29","paymentDate":"2020-06-30","value":0.2782635,"currency":"USD"},{"executeDate":"2020-09-15","recordDate":"2020-09-16","paymentDate":"2020-09-30","value":0.2792338,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NETL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NETL\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655806836","title":"AvalonBay Communities（AVB）與Equity Residential（EQR）合併 房地產投資信託基金預估市值可達530億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655806836","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655806836?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 22:15","pubTimestamp":1785420930,"startTime":"0","endTime":"0","summary":"本次合并将打造规模庞大的长租公寓运营平台，合并完成后的房地产投资信托基金预估市值可达530亿美元，企业价值约710亿美元。消息传出后，二级市场股价出现波动，AvalonBay早盘下跌1.4%，Equity Residential股价下跌1.6%，市场持续观望本次合并后续整合方案与运营规划。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303239","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VGSR","SPHD","NURE","BK4215","VRAI","MDIV","XSHD","CRIB","BK4588","ABLD","BK4585","IDGT","INDS","NETL","CSRE","ASET","PPTY","RNTY","SPRE","EQR","IVRA","FREI","DPRE","AVRE","BLDG","ALTY","BK4007","DTRE","AVB","DFRA","IQRA","REZ","KBWD","IYLD","GRI","JPRE","GARA","RWO","RITA","HIPS","BK4139","BK4550","REAI","FPRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655712728","title":"科倫藥業(002422.SZ)：TROP2 ADC蘆康沙妥珠單抗(sac-TMT)新增適應症上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655712728","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655712728?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 19:31","pubTimestamp":1785411100,"startTime":"0","endTime":"0","summary":"此前，芦康沙妥珠单抗用于一线治疗不可手术切除的局部晚期、复发或转移性PD-L1阴性TNBC已获NMPA授予突破性疗法认定。本次新增适应症上市申请亦已纳入优先审评审批程序，成为芦康沙妥珠单抗纳入该程序的第六项上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1064130708.USD","BK4080","LU1064131003.USD","LU1979443071.USD","BK0060","BK4231","IPOS","LU1934453819.USD","NETL","LU2148510915.USD","ADC","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655881059","title":"受租金收入增長提振，VICI上調了2026年基金運營收入（FFO）預測","url":"https://stock-news.laohu8.com/highlight/detail?id=2655881059","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655881059?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 06:45","pubTimestamp":1785365108,"startTime":"0","endTime":"0","summary":"受租金收入增长提振，VICI上调了2026年基金运营收入预测路透7月29日-VICI Properties上调了2026年调整后运营现金流预测的下限，因该公司在本季度新增了三家租户，从而实现了租金收入来源的多元化和增长。该公司目前预计2026年每股调整后基金运营收益将在2.45美元至2.47美元之间，高于此前预期的2.44美元至2.47美元。不过，VICI本季度每股经调整基金从运营中获得的收益为62美分，低于分析师预期的每股67美分该股在盘后交易中下跌0.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4T43V2PN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NETL","BK4588","TSRS","BK4561","VICI","BK4234","GQRE","BK4084"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171830503","title":"VICI Properties 更新2026財年調整後運營資金指引：上調至26.75億-27億美元，每股2.45-2.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171830503","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171830503?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 05:09","pubTimestamp":1785359381,"startTime":"0","endTime":"0","summary":"VICI Properties 今日宣布，其2026财年调整后运营资金（Adjusted Funds From Operations）指引已更新。最新预测显示，公司预期该指标总额将达到26.75亿至27亿美元之间。换算为每股收益，则落在2.45美元至2.47美元的区间内。这一调整反映了公司对业务前景的重新评估与信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSRS","BK4588","BK4585","NETL","BK4234","BK4084","BK4561","VICI","GQRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654395072","title":"Sonesitatug vedotin 在 CLDN18.2陽性晚期胃癌/胃食管結合部癌的二線及後線治療中，顯示出具有統計學顯著性且重要臨床意義的總生存期（OS）改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2654395072","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654395072?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 12:18","pubTimestamp":1785212280,"startTime":"0","endTime":"0","summary":"关于胃癌和胃食管结合部癌 胃癌是全球第五大常见癌症，也是癌症相关死亡的第五大原因。关键次要终点为二线及后线治疗人群的总生存期。CLDN18.2是一种存在于胃黏膜上皮中的蛋白，已被验证为肿瘤治疗领域的重要治疗靶点，尤其在胃肠道肿瘤中具有重要意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CBOA","CBTA","CBTO","CBXJ","CBXY","DEFI","FBTC","AZN","AZNH","HODL","BTCL","BITX","ADC","CBXA","BTFX","BITY","ARKB","BITO","QBF","SBIT","BETH","CBOJ","COAL","BETE","BTCO","EAC","IBIT","BTC","BCCC","NETL","MNRS","YBTC","EZBC","BTRN","CBTJ","BRRR","XBTY","CBTY","MAXI","BITU","HCC","IBBQ","BTCZ","BTCI","PFS","BTCW","BFJL","BITI","CBXO","IHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654224045","title":"科倫藥業(002422.SZ)：科倫博泰新型雙載荷ADC藥物SKB565新藥臨床試驗(IND)申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2654224045","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654224045?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 22:16","pubTimestamp":1785161788,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业 发布公告，公司近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司已收到国家药品监督管理局药品审评中心同意新型双载荷ADC药物SKB565新药临床试验申请的临床试验通知书，用于治疗晚期实体瘤。这是科伦博泰首个进入临床阶段的双载荷抗体偶联药物。据悉，SKB565是科伦博泰“ADC+IO”一体化开发策略的核心代表药物之一，基于科伦博泰专有的OptiDCTM平台开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NETL","PSYK","IBBJ","BK4231","LU2148510915.USD","LU1064130708.USD","LU1934453819.USD","IBBQ","LU1979443071.USD","ADC","BK0239","IND","BMED","LU1064131003.USD","MDTX","002422","BK4080","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654936970","title":"英派藥業首個雙載荷ADC成果落地：IMP3201被提名為臨床前候選化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=2654936970","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654936970?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 09:06","pubTimestamp":1785114360,"startTime":"0","endTime":"0","summary":"7月27日，英派药业（07630）发布公告，宣布IMP3201被提名为临床前候选化合物（PCC），这是基于公司自主研发的双载荷ADC平台的首个成果。IMP3201是一种靶向CEACAM5的双载荷ADC，采用优化的摩尔比搭载Exatecan及公司专有的ATR抑制剂。该化合物旨在治疗胃肠道恶性肿瘤，包括结直肠癌、胰腺癌、胃癌及食管鳞状细胞癌，以满足临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273821349058.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273821349058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","BK4231","NETL","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654639210","title":"百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2654639210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654639210?lang=zh_tw&edition=fundamental","pubTime":"2026-07-26 15:48","pubTimestamp":1785052138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的创新生物药注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中对比T-Bren与医生选择的化疗的III期随机对照临床试验已于近日完成首例受试者入组。据悉，T-Bren是一种靶向HER2的创新型ADC，具有同类最佳潜力，已在临床试验中展示出显著的抗肿瘤功效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","PSYK","91194","BK4231","02615","MDTX","688506","IBBJ","NETL","BMED","BK0239","BK4080","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652903211","title":"Biohaven將在ESMO大會公布BHV-1530 ADC新藥臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2652903211","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652903211?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 22:25","pubTimestamp":1784557500,"startTime":"0","endTime":"0","summary":"生物制药公司Biohaven周一宣布，将在即将举行的欧洲肿瘤内科学会大会上公布其新型FGFR3靶向抗体偶联药物BHV-1530的临床数据。BHV-1530搭载了公司专有的拓扑异构酶I抑制剂有效载荷。　　Biohaven在新闻稿中表示，此次公布的数据将包括BHV-1530在晚期实体瘤患者中的首次人体临床试验初步结果，重点评估药物的安全性、耐受性和初步抗肿瘤活性。Biohaven的BHV-1530数据将在大会的“新药物”专题环节中以口头报告形式呈现。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-20/doc-iniinmvy8222546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","ADC","BHV","NETL","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651246129","title":"科倫博泰TROP2 ADC實現「全球首個」：PD-L1陰性一線NSCLC III期達PFS主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2651246129","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651246129?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 22:38","pubTimestamp":1784126286,"startTime":"0","endTime":"0","summary":"7月15日早间，科伦博泰（HK06990，股价536.50港元，市值1282.36亿港元）宣布其TROP2ADC药物芦康沙妥珠单抗（佳泰莱?）联合帕博利珠单抗（可瑞达?）一线治疗PD-L1阴性非鳞状非小细胞肺癌的III期研究（OptiTROP-Lung06）在期中分析中达到无进展生存期主要终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807804934.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807804934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4195","III","NETL","PFS","BK4211","LU1169589451.USD","PD","ADC","BK4080","LU1169590202.USD","BK4231","BK4134","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145968","title":"消息人士稱，AirTrunk計劃於9月或10月在新加坡推出房地產投資信託基金首次公開發行，有望籌資約15億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145968?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 17:39","pubTimestamp":1784108365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["VRAI","REAI","AVRE","ALTY","MDIV","BK4588","SPHD","HIPS","XSHD","IVRA","BK4139","ABLD","NETL","VGSR","BK4007","IQRA","ASET","INDS","JPRE","RWO","KBWD","SPRE","IYLD","GRI","BK4585","CSRE","IDGT","DTRE","FPRO","BK4550","BLDG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651043069","title":"美國研究綜述-Equinix、高盛、摩根大通","url":"https://stock-news.laohu8.com/highlight/detail?id=2651043069","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651043069?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 15:24","pubTimestamp":1784100290,"startTime":"0","endTime":"0","summary":"美国研究综述-Equinix、高盛、摩根大通路透7月15日-周三，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括Equinix、高盛和摩根大通。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nL4S43H0J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DKUP","EGP","BYD","EXR","FRT","JLL","PENN","HCA","RWR","FBP","IDGT","FREL","VAN","SRVR","CCI","KHC","CHEF","ADC","GS","AKR","OFG","AIR","AHR","ITA","BXP","LVS","LXP","PTCT","CELC","DLR","JPM","IVT","BRX","EQIX","BPOP","CDP","GE","NETL","AMT","MAC","PFGC","IHF","CHRW","KIM","LSTR","BAC","VGSR","LGND","DKNG","KRG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651436406","title":"科倫藥業：TROP2 ADC聯合療法肺癌3期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2651436406","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651436406?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 11:58","pubTimestamp":1784087937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ADC","BK4231","NETL","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651637482","title":"超2萬億元！上海三大先導產業交出倍增答卷","url":"https://stock-news.laohu8.com/highlight/detail?id=2651637482","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651637482?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 06:26","pubTimestamp":1784067962,"startTime":"0","endTime":"0","summary":"2020年，上海市“十四五”规划建议明确提出：推动集成电路、生物医药、人工智能三大先导产业规模倍增。当年，上海三大先导产业规模总体约1万亿元。今年初，回顾2025年的上海政府工作报告传递明确数字：2025年，上海三大先导产业规模突破2万亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153806297375.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153806297375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1481600234.SGD","AIBU","SMHX","LU1481599808.USD","ADC","SMH","TEKX","VGT","BK4136","PSI","CUT","WOOD","BK4588","LU1169589451.USD","IP","SSG","CHPS","LU1169590202.USD","TARK","SOXS","BK4581","FTXL","BK4231","IE00B3T34201.USD","SOXQ","XBI","USD","AIFD","SOXY","KOMP","QTOC","LU2463526074.USD","BK4585","SOXX","FWD","VTHR","NETL","LU1487256676.USD","BK4080","NBDS","IPOS","SOXL","BK4535","CHAT","CHPY","XSD","AGIX","AIPO","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651132051","title":"據天空新聞報道，英國超市莫里森斯正就一筆價值8.03億美元的門店交易進行談判","url":"https://stock-news.laohu8.com/highlight/detail?id=2651132051","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651132051?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 18:39","pubTimestamp":1783939191,"startTime":"0","endTime":"0","summary":"据天空新闻报道，英国超市莫里森斯正就一笔价值8.03亿美元的门店交易进行谈判路透7月13日-据天空新闻周一援引行业消息人士报道，英国超市集团莫里森斯（Morrisons）正与包括美国房地产投资信托基金Realty Income（O.N）在内的多家机构就一笔价值6亿英镑（8.0298亿美元）的房地产交易进行谈判。路透无法立即核实该报道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nL4S43F0TB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4080","ERET","O","DFAR","SRHR","RWR","BK4231","NETL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650906760","title":"港股異動 | 百奧賽圖-B(02315)升逾14% 近日與Whitehawk達成全球合作 共同開發創新雙特異性抗體ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2650906760","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650906760?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 11:10","pubTimestamp":1783653039,"startTime":"0","endTime":"0","summary":"根据协议，百奥赛图将通过其自主研发的RenLite平台提供至多五款全人双特异性抗体，Whitehawk将结合其ADC连接子-载荷平台技术对这些抗体进行评估。Whitehawk随后可选择将由此产生的BsADC候选分子纳入其管线并推进开发。通过整合百奥赛图与Whitehawk的互补优势，本次合作旨在发掘具有差异化靶向机制和治疗潜力的BsADC候选分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","BK1161","BK4080","KCAI","BK4588","688796","BK4585","ADC","BK4231","VXUS","BK0216","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649994721","title":"豪華酒店房地產投資信託基金Braemar Hotels & Resorts回應Al Shams不實指控","url":"https://stock-news.laohu8.com/highlight/detail?id=2649994721","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649994721?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 22:30","pubTimestamp":1783521000,"startTime":"0","endTime":"0","summary":"豪华酒店房地产投资信托基金Braemar Hotels & Resorts Inc．发布声明，就最大股东Al Shams Investments Limited及其主要负责人Wafic Said近期的一系列公开言论作出回应，称其指控毫无根据，并质疑Said的动机与过往记录。　　Braemar表示，尽管多次尝试与Said进行建设性沟通，但均遭拒绝。　　Braemar Hotels & Resorts是一家专注于豪华酒店和度假村领域的房地产投资信托基金，其投资组合涵盖美国本土及加勒比海地区的优质酒店资产。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-08/doc-inihceis8353217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HIPS","IVRA","BLDG","INDS","IDGT","IQRA","IYLD","ASET","FPRO","GRI","BK4585","AVRE","SPHD","BK4007","KBWD","BK4139","NETL","ABLD","MDIV","VGSR","JPRE","RWO","CSRE","BK4588","SPRE","VRAI","DTRE","REAI","BK4550","XSHD","ALTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649499680","title":"安捷倫(A)擴充Altura色譜柱產品線兩款新品 適配多肽、ADC、mRNA等生物藥檢測","url":"https://stock-news.laohu8.com/highlight/detail?id=2649499680","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649499680?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 20:32","pubTimestamp":1783513936,"startTime":"0","endTime":"0","summary":"两款新品搭载安捷伦超惰性分离技术，是原有 Altura 液相耗材矩阵的重要补充。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NjQzZWIwYjMxODE0NDMwMmFiMWMzYWFhZmVlYWI3MGY0MzQwNTkyOTA0MzE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjQzZWIwYjMxODE0NDMwMmFiMWMzYWFhZmVlYWI3MGY0MzQwNTkyOTA0MzE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302338","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2413666426.HKD","LU0347712357.USD","LU1543694498.USD","IE00BN0W2T93.GBP","LU2229751404.USD","BK4231","BK4585","LU1721429741.USD","LU2089279066.USD","BK4588","LU1721429402.USD","LU2413666699.HKD","BK4121","NETL","LU2092937221.SGD","BK4567","BK4080","LU1721428933.USD","159839","LU1165135440.EUR","LU2041044095.USD","IE00BN0W2V16.EUR","ADC","A","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649137647","title":"從「旁觀者」到「追趕者」：諾華(NVS.US)斥資15億美元收購Myricx，ADC賽道再落關鍵一子","url":"https://stock-news.laohu8.com/highlight/detail?id=2649137647","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649137647?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 17:02","pubTimestamp":1783328521,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华已就收购英国生物技术企业Myricx Bio达成协议，交易总对价最高可达15亿美元。据诺华周一发布声明，Myricx股东将获得11亿美元预付款，以及最高4亿美元的潜在里程碑付款。2025年10月，诺华以120亿美元收购了Avidity Biosciences，成为当年规模最大的抗体相关交易。此次收购Myricx，正是其深耕肿瘤学核心领域、充实ADC管线的关键落子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","IE00B2B36J28.USD","BK4231","IE00B4R5TH58.HKD","IE0009355771.USD","NVS","ADC","LU0320765489.SGD","BK4585","IE00BJT1NW94.SGD","BK4007","LU0211331839.USD","LU0208291251.USD","BK4588","BK4532","NETL","PPH","BK4578","BK4080","IE0002141913.USD","LU0070302665.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156175490","title":"Realty Income攜手Cloud Capital及全球機構投資者組建程序化合資企業，投資超大規模數據中心，初始種子資產估值超60億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156175490","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156175490?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 15:45","pubTimestamp":1783323923,"startTime":"0","endTime":"0","summary":"6月30日 - Realty Income Corp宣布，其已与Cloud Capital及一家全球机构投资者组建一家程序化合资企业，旨在投资于超大规模数据中心领域。该合资企业的初始种子资产组合估值已超过60亿美元。\n根据公告，Realty Income Corp预计将投资高达14亿美元，以获取一个位于北弗吉尼亚州的三资产投资组合中45%的股权权益。该合资企业的收购计划分步进行：预计将于2026年第三季度收购一项已稳定运营的资产，并将在未来日期收购另外两项尚在开发中的资产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","NETL","ERET","RWR","O","DFAR","BK4231","SRHR","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}]}}